Monopar Therapeutics Inc. (NASDAQ:MNPR – Get Free Report) was the recipient of a significant increase in short interest during the month of February. As of February 28th, there was short interest totalling 51,300 shares, an increase of 57.8% from the February 13th total of 32,500 shares. Currently, 1.3% of the company’s stock are sold short. Based on an average daily trading volume, of 66,900 shares, the days-to-cover ratio is currently 0.8 days.
Analyst Ratings Changes
A number of research analysts have commented on the company. HC Wainwright increased their target price on Monopar Therapeutics from $22.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, January 22nd. Piper Sandler began coverage on shares of Monopar Therapeutics in a report on Friday, January 10th. They issued an “overweight” rating and a $72.00 price objective for the company.
Read Our Latest Stock Analysis on MNPR
Monopar Therapeutics Price Performance
Hedge Funds Weigh In On Monopar Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. acquired a new position in Monopar Therapeutics during the 4th quarter worth $45,000. Geode Capital Management LLC increased its stake in Monopar Therapeutics by 174.4% during the 4th quarter. Geode Capital Management LLC now owns 38,596 shares of the company’s stock valued at $849,000 after buying an additional 24,530 shares during the period. ADAR1 Capital Management LLC acquired a new stake in shares of Monopar Therapeutics in the 4th quarter worth approximately $2,861,000. Point72 Asset Management L.P. acquired a new stake in shares of Monopar Therapeutics in the 4th quarter worth approximately $3,694,000. Finally, RA Capital Management L.P. bought a new position in shares of Monopar Therapeutics in the fourth quarter valued at approximately $11,247,000. Institutional investors and hedge funds own 1.83% of the company’s stock.
Monopar Therapeutics Company Profile
Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
Further Reading
- Five stocks we like better than Monopar Therapeutics
- Find and Profitably Trade Stocks at 52-Week Lows
- The “Quality” Rotation: Back to Basics Investing
- What is a Death Cross in Stocks?
- Occidental Petroleum: 4 Reasons to Love These Prices
- How to Invest in Insurance Companies: A GuideĀ
- Super Micro’s International Presence Makes It a Winning Stock
Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.